Beyond Air, Inc. (NASDAQ:XAIR) Sees Large Decrease in Short Interest

Beyond Air, Inc. (NASDAQ:XAIR) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 966,700 shares, a decrease of 16.7% from the December 31st total of 1,160,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the short-interest ratio is currently 0.8 days.

Beyond Air Trading Up 0.8 %

NASDAQ:XAIR opened at $0.38 on Monday. Beyond Air has a 52 week low of $0.30 and a 52 week high of $2.17. The stock has a market cap of $27.66 million, a price-to-earnings ratio of -0.27 and a beta of -0.17. The company’s 50 day moving average price is $0.44 and its 200-day moving average price is $0.44. The company has a quick ratio of 5.38, a current ratio of 5.76 and a debt-to-equity ratio of 0.37.

Beyond Air (NASDAQ:XAIR) last posted its earnings results on Monday, November 11th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. The business had revenue of $0.80 million during the quarter, compared to analyst estimates of $1.19 million. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. During the same quarter last year, the company earned ($0.51) EPS. On average, equities research analysts forecast that Beyond Air will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Beyond Air

Hedge funds have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in Beyond Air in the second quarter valued at about $47,000. Baldwin Wealth Partners LLC MA increased its position in shares of Beyond Air by 721.3% during the 4th quarter. Baldwin Wealth Partners LLC MA now owns 308,000 shares of the company’s stock valued at $110,000 after purchasing an additional 270,500 shares during the last quarter. Finally, Soros Fund Management LLC bought a new position in shares of Beyond Air in the 3rd quarter worth approximately $573,000. 31.50% of the stock is currently owned by hedge funds and other institutional investors.

About Beyond Air

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.